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tions highlighted that response-shift effects may be a result of the
instruments used. Individualized (generic) QoL -instruments can
be prone to response-shift effects due to their conceptualization
addressing a broad range of life aspects. In contrast, disease-
speciﬁc PRO measures focusing on speciﬁc aspects of disease are
less affected by response-shift phenomena.
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OBJECTIVES: According to international surveys, half of the
subjects with indications for statin therapy are treated and half
the treated subjects is still adherent after six month from starting
therapy. Poor adherence to statin therapy is the main factor of
cardiovascular prevention failure and health care costs increase.
Unfortunately, tools to support stakeholders in monitoring
current medical practice are unavailable. The aim of our work
was to perform a population-based retrospective analysis to
evaluate the characteristics of patients treated with statins and
their adherence to treatment through the linkage of administra-
tive databases of the LHS of Ferrara (approximately 350,000
beneﬁciaries). METHODS: All subjects aged >18 years receiving
at least a prescription for statins between January 1st, 2004 and
June 31st, 2005 were enrolled. In each subject we recorded age,
sex, concurrent chronic therapy, previous hospital admissions
and, starting from the ﬁrst prescription, a treatment proﬁle in the
following 6 months. Adherent subjects were deﬁned as having a
PDD-standardized (mean daily dose/PDD) >0.8. The pharmaco-
logical patterns were compared among three periods lasting 6
months each. RESULTS: Treated subjects decreased from 20,445
and 20.221 of the ﬁrst two periods to 17,756 of the third period
mainly for reduction of newly treated subjects (from 5,108 and
4342 to 3,688). Newly treated in the third period were more
frequently male, older and showed a higher prevalence of con-
current drug treatments and of previous cardiovascular hospital-
izations. Adherent subjects increased from 29,7% and 31.9% in
ﬁrst two periods to 45.4% in third period (OR 1648, CI 1.579–
1.721, p < 0.001). CONCLUSION: Poor adherence was associ-
ated with younger age, lower prevalence of concurrent drug
treatments and of previous cardiovascular hospitalizations.
Adequate systems are required to monitor and assess actual
practice, to highlight and size critical areas, to account stake-
holders for practice improvement through adherence to standard
rather than for cost containment.
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OBJECTIVES: The National Cholesterol Education Program
ATP III (ATPIII) guidelines notes that patient persistence to lipid-
lowering therapy is suboptimal. Persistence is especially impor-
tant because patients with hyperlipidemia typically require
long-term treatment. ATPIII further notes that adherence appears
to be unrelated to sex, age, ethnicity, or socioeconomics. Given
that women and racial minorities are less likely to achieve ATPIII
lipid goals, we sought to retrospectively examine the relationship
between speciﬁc demographics and the likelihood of discontinu-
ing antilipidemic medications. METHODS: Retrospective claims
analysis of Florida Medicaid adults (age18 years) who initiated
antilipidemics during 1997–2006, and who had 1 year of data
prior to, and 3 years of data following, their ﬁrst antilipidemic
claim. Premature discontinuation was deﬁned as no antilipidemic
claim for at least 6 months during the 3 year follow-up. Chi-
square examined categorical variables and Cox proportional
hazard examined demographic (sex, age, race/ethnicity) predic-
tors of discontinuation. RESULTS: Of 75,726 patients initiating
antilipidemics, most (68.8%; n = 52,085) were female and age
50 years (75.7%; n = 57,333); 42.7%, (N = 32,350) were
White, 18.5% (n = 14,015) Black, 9.5% (n = 7,163) Hispanic,
and 29.3% (n = 22,198) other races/ethnicities. Hispanics were
45%, other races/ethnicities 30%, and Blacks 7% more likely
to discontinue treatment (all p < 0.0001) than Whites. Younger
patients (<50 years) were 18% more likely to discontinue treat-
ment than older (>70 years) patients (p < 0.0001), and females
were 8% more likely to discontinue treatment than males
(p < 0.0001). CONCLUSION: Compared to ATPIII, which
reports that antilipidemic persistence is unrelated to demograph-
ics, we found antilipidemic persistence to be signiﬁcantly associ-
ated with patient sex, age, and race/ethnicity. However, our
results are consistent with those of other recent retrospective
studies that report a signiﬁcant relationship between demograph-
ics and adherence to lipid-lowering therapy. Poor persistence
may, in part, explain lower rates of achieving ATPIII lipid goals
seen among women and racial/ethnic minorities.
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OBJECTIVES: Chronic disease therapies have to be taken for
long periods, usually indeﬁnitely; hence the risk of discontinua-
tion is often high. Low compliance/persistence may compromise
the potential beneﬁts of treatment. The purpose of this study was
to investigate patients’ adherence and persistence to therapy with
hypolipemic medications using a large administrative database.
METHODS: We used the Regione Lombardia Health Service
(RLHS) administrative databases, which contain information on
a population of >9 millions individuals with universal health care
and pharmaceutical coverage. The study population included
individuals with at least one prescription of a hypolipemic agent
during the year 2003 and who were enrolled in the RLHS in the
year 2003. Persistence and adherence was evaluated with the
medication possession ratio (MPR), calculated as the ratio
between the number of pills dispensed during the study period
and the number of days of observation. MPR was estimated for
individuals who ﬁlled their ﬁrst prescription in the year before 31
October 2003. RESULTS: Out of a population of 9,108,645
members, 560,737 (6.2%) received at least one prescription of a
study drug. Frequency of use increased from 0.7% in subjects
with age <40 years to 18.4% in subjects age 70–79 y.o. A total of
16.2% of subjects received one or two packs during the study
period, the median number of packs prescribed was 14, and
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simvastatin (35.4%), atorvastatin (27.6%) and pravastatin
(13.2%) were the most prescribed initial drugs. A total of
503,023 patients were considered for the adherence analysis:
34.9% of subjects had MPR < 0.4; 34.7% between 0.4 and 0.8;
and 30.4% > 0.8. CONCLUSION: Persistent and adherence
with hypolipemic medications is far from optimal in this large
cohort of subjects. This phenomenon is common to many asymp-
tomatic chronic therapies and deserves further investigations, as
it indicates that a relevant part of drug resources are spent
without a predictable clinical beneﬁt.
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OBJECTIVES: Combination pharmacotherapy is often necessary
to treat hypertension, but can negatively impact patient compli-
ance. This analysis assesses the impact of combination therapy
with valsartan and amlodipine, with or without hydrochlorthi-
azide (HCTZ), on medication possession ratios (MPR) in a
previously antihypertensive naïve population. METHODS: A
national database of insured hypertensive patients > age 18 pre-
viously antihypertensive naïve was evaluated for combination
pharmacotherapy. Dual therapy with valsartan and amlodipine
was initiated within the ﬁrst 180 days of pharmacotherapy.
Triple therapy with valsartan-amlodipine-HCTZ could occur in
two manners during the ﬁrst 365 days of pharmacotherapy:
combination as three free drug components, or a proprietary
ﬁxed dose combination of valsartan and HCTZ with amlodipine.
All three groups had at least two claims for the combination
during the 365 days following initiation of the combination.
RESULTS: Using hypertension ICD-9 codes (401.0, 401.1,
401.9, 402.1 & 402.9) 908 subjects met study criteria for com-
bination pharmacotherapy: 224 on dual therapy, 63 on free triple
therapy, and 615 on ﬁxed dose triple therapy. MPR values
decreased with the increase in tablets per regimen: dual therapy
0.779, ﬁxed dose triple 0.734, free triple 0.694 (P = 0.0149). A
trend towards improved MPR with increasing age was noted
between cohorts, and in the general population increased from
0.7 in ages 18–35 to 0.77 for subjects > 65 (P = 0.0058) A trend
towards improved MPR with increasing severity of cardiovascu-
lar disease was also noted. MPR values for subjects with the
highest disease burden (>2 comorbid cardiovascular diseases)
followed a similar pattern: dual 0.791, triple ﬁxed 0.745, triple
free 0.654 (P = 0.067). CONCLUSION: Patient compliance
improves with simpliﬁed pharmacotherapy approaches. Dual
therapy provided the best MPR values, followed by triple drug
therapy using two tablets (ﬁxed dose valsartan HCTZ plus amlo-
dipine). Other factors positively inﬂuencing compliance were
advancing age and overall cardiac disease burden.
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OBJECTIVES: The study evaluates adherence with antihyper-
tensive drug treatments in newly treated patients, outlines char-
acteristics of patients discontinuing treatment (discontinuation
risk proﬁling), and calculates amount of resources allocated on
not effective treatment patterns (eg, discontinuation). An admin-
istrative database kept by the Local Health Unit of Pavia listing
patient baseline characteristics, drug prescriptions and hospital
admissions was used to perform a population-based retrospec-
tive analysis. METHODS: The study included all newly treated
users of antihypertensive drugs, 18 years of age, receiving a
ﬁrst prescription for diuretics, beta-blockers, calcium channel-
blockers, ACE inhibitors, angiotensin II antagonists or other
antihypertensive drugs between January 1st, 2001 and Decem-
ber 31st, 2003. Patients were observed for 365 days. Adherent
patients were deﬁned as having a duration of therapy >273 days
and DDD-standardized mean daily dose 0.8. RESULTS: A
total of 42,000 patients were included in the study.Excluding
ACE inhibitors (34.3%) other antihipertensive classes were
included in a range from 13.3% up to 18.8%. The 75.1% of
patients was not adherent to antihypertensive treatment. Those
prescribed with angiotensin II antagonists were more likely to
adhere treatment than those started on other antihypertensive
classes. Poor adherence was associated with younger age, lower
prevalence of concurrent chronic pharmacotherapies and lower
prevalence of previous hospitalizations for cardiovascular dis-
eases. The overall cost amounted to € 5.320 mio € of which
36.4% was accounted for not adherent patients. CONCLU-
SION: The clinical, social, and economic importance of treating
hypertension requires the analysis and the implementation of
tools for monitoring antihypertensive drug utilization as to
assess the extent to which results from clinical research are
brought into clinical practice. Administrative databases offer a
powerful and low cost tool, providing detailed and useful,
population-wide epidemiological and economic information for
antihypertensive drug utilization.
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